Precision medicine brings new focus to prostate cancer treatment
Enhancing diagnostic accuracy to improve patient outcomes.
As prostate cancer care continues to evolve, cutting-edge imaging and biomarker technologies are rapidly reshaping clinical decision-making by improving diagnostic accuracy and, ultimately, leading to more personalized approaches to care.
“Biomarkers and PSMA imaging are central to the management of all stages of prostate cancer, from newly diagnosed disease to metastatic,” said Adam Kibel, MD, one of the presenters in today’s session, “Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer,” 2-4 p.m. in Venetian H. “Our session will ensure that providers fully understand how to use these critical tools to optimize patient care.”
Dr. Kibel, chair of urology at Mass General Brigham in Boston and the Elliot Carr Cutler Professor of Surgery at Harvard Medical School, will join Evan Yu, MD, section head of medical oncology at Fred Hutchinson Cancer Center, Robert Reiter, MD, Bing Professor of Urologic Oncology and chief of the urologic oncology division at UCLA, and Steven Rowe, MD, PhD, assistant professor in the Russell H. Morgan Department of Radiology and Radiological Science at Johns Hopkins, for this CME-accredited session offering an in-depth exploration into how these tools are transforming diagnosis, staging and treatment selection for patients across the disease spectrum.
During this session, participants will gain practical insights into determining the right clinical scenarios for deploying PSMA PET/CT, recognizing its strengths and limitations and translating imaging findings into tailored therapeutic plans. With recent studies highlighting the sensitivity and specificity of PSMA-targeted imaging, this session arrives at a crucial time for clinicians looking to enhance diagnostic accuracy and improve patient outcomes.
In addition to PSMA imaging, the session will cover emerging biomarkers and how they contribute to more precise staging, recurrence detection and treatment monitoring.
Presenters will also define patient selection strategies for those with radio-recurrent and organ-confined prostate cancer—helping urologists identify candidates most likely to benefit from advanced imaging techniques.
With leading experts and practical insights, this session is a must-attend for clinicians aiming to stay at the forefront of prostate cancer care. Whether managing early-stage disease or guiding advanced cases, the knowledge shared here will directly impact your ability to deliver more precise, personalized treatment.
